Literature DB >> 27898987

Improving the Accelerated Pathway to Cancer Drug Approvals.

Scott R Bauer, Rita F Redberg.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 27898987     DOI： 10.1001/jamainternmed.2016.7777

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  2 in total

1.  Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials.

Authors:  Jeremy M O'Connor; Kristen L Fessele; Jean Steiner; Kathi Seidl-Rathkopf; Kenneth R Carson; Nathan C Nussbaum; Emily S Yin; Kerin B Adelson; Carolyn J Presley; Anne C Chiang; Joseph S Ross; Amy P Abernethy; Cary P Gross
Journal:  JAMA Oncol       Date:  2018-08-09       Impact factor: 31.777

2.  Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases.

Authors:  Sumimasa Nagai; Keiya Ozawa
Journal:  Invest New Drugs       Date:  2018-02-17       Impact factor: 3.850
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.